Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma 
Welcome,         Profile    Billing    Logout  
 30 Diseases   8 Trials   8 Trials   318 News 


«123456»
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    Trial primary completion date:  Efficacy of Prednisolone Versus Cerebrolysin in the Treatment of Bell's Palsy (clinicaltrials.gov) -  Oct 30, 2023   
    P1/2,  N=90, Recruiting, 
    These observations are the first to show that spinal cord injury induces Alzheimer's disease like symptoms in the CNS, not reported earlier. Trial primary completion date: Sep 2023 --> Dec 2023
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    Retrospective data, Journal:  A retrospective study of Cerebrolysin in patients with moderate to severe traumatic brain injury: Cognitive and functional outcomes. (Pubmed Central) -  Oct 30, 2023   
    Specifically, patients who received Cerebrolysin showed a moderate residual disability and a significant reduction in the need for care. Concerning the promising results and considering the limitations of the retrospective study design, we suggest that randomized controlled studies be initiated to corroborate the positive findings for Cerebrolysin in patients with moderate to severe brain trauma.
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    Clinical, Retrospective data, Review, Journal:  Cerebrolysin in Patients with Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis. (Pubmed Central) -  Oct 28, 2023   
    The data suggest a positive effect of Cerebrolysin on the mortality of SAH patients. However, further randomized clinical trials with larger groups of patients are needed to draw final conclusions.
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    Review, Journal:  Cerebrolysin for acute ischaemic stroke. (Pubmed Central) -  Oct 11, 2023   
    Moderate-certainty evidence suggests that Cerebrolysin probably has no beneficial effect on the total number of people with serious adverse events. Moderate-certainty evidence also indicates a potential increase in non-fatal serious adverse events with Cerebrolysin use.
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    Trial initiation date:  CERICA: CERebrolysin In CADASIL (clinicaltrials.gov) -  Sep 7, 2023   
    P2,  N=30, Not yet recruiting, 
    However, no difference in functional outcome was found on day 90, but there was a trend towards favorable functional outcome. Initiation date: Apr 2023 --> Oct 2023
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    Clinical, Review, Journal:  Pharmacological treatment in early rehabilitation after ischemic stroke (Pubmed Central) -  Aug 29, 2023   
    This review provided a summary of the evidence on pharmacological supportive care in early rehabilitation of post-acute ischemic stroke patients. This will make it possible to improve current recommendations with the aim of collaborating with health decision-making for this population.
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    Review, Journal:  Post-COVID-19 Anosmia and Therapies: Stay Tuned for New Drugs to Sniff Out. (Pubmed Central) -  Jun 27, 2023   
    The other interesting drugs are 13-cis-retinoic acid plus aerosolized Vitamin D, dexamethasone, and corticosteroid nasal irrigation...Some of these therapies are very promising and are almost at the end of experimentation. They also provide hope in this field, which not addressed until recently.
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    Journal:  Optimized approach for active peptides identification in Cerebrolysin by nanoLC-MS. (Pubmed Central) -  Jun 16, 2023   
    In addition, this study found that some peptides in CBL were present in myelin basic protein and tubulin beta chain. The results of this study for the detection of active peptides in CBL laid the foundation for the subsequent study of its active ingredients.
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    Preclinical, Journal:  Cerebrolysin Amelioration of Spinal Cord Ischemia/ Reperfusion Injury in Rabbit Model. (Pubmed Central) -  Jun 13, 2023   
    The results of this study for the detection of active peptides in CBL laid the foundation for the subsequent study of its active ingredients. For the first time in the literature the current study reports anti-inflammatory, antioxidant, antiapoptotic, and neuroprotective effects of cerebrolysin in a SCIRI rabbit model.
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    Journal, HEOR, Cost-effectiveness, Cost effectiveness:  Cost-Effectiveness of Cerebrolysin after Ischemic Stroke: Secondary Analysis of the CARS Study. (Pubmed Central) -  May 27, 2023   
    These should be conducted to determine its cost-effectiveness under various care settings and patient pathways. Most importantly, modelling techniques are needed to answer important questions such as the estimates of population gain in QALYs after acute administration of Cerebrolysin and the potential offsetting of direct medical costs as a result of administering the intervention.
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    Trial completion date, Trial primary completion date:  Efficacy and Safety of Cerebrolysin on Prolonged Disorders of Consciousness (clinicaltrials.gov) -  May 26, 2023   
    P4,  N=12, Not yet recruiting, 
    Most importantly, modelling techniques are needed to answer important questions such as the estimates of population gain in QALYs after acute administration of Cerebrolysin and the potential offsetting of direct medical costs as a result of administering the intervention. Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Jul 2025
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    Trial completion date, Trial primary completion date:  Efficacy and Safety of Cerebrolysin on Prolonged Disorders of Consciousness (clinicaltrials.gov) -  May 24, 2023   
    P4,  N=12, Not yet recruiting, 
    Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Jul 2025 Trial completion date: Sep 2023 --> Dec 2024 | Trial primary completion date: Jun 2023 --> Dec 2024
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    Enrollment status:  Efficacy of Prednisolone Versus Cerebrolysin in the Treatment of Bell's Palsy (clinicaltrials.gov) -  May 6, 2023   
    P1/2,  N=90, Recruiting, 
    Our findings indicated that CBL, separately or in combination with EE, is effective in reducing anxiety and spatial memory impairment in PTSD-like mice. Enrolling by invitation --> Recruiting
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    Journal:  Cerebrolysin in the treatment of cognitive impairment (Pubmed Central) -  Mar 25, 2023   
    The experience of many years of clinical use of Cerebrolysin testifies not only to its high efficiency, but also to its safety. It should be taken into account that similar substances can be developed in relation to biological products - biosimilars or biosimilars, which can be considered comparable only in case of equivalent pharmacokinetic parameters, efficacy and safety.
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    New P2 trial:  CERICA: CERebrolysin In CADASIL (clinicaltrials.gov) -  Mar 6, 2023   
    P2,  N=30, Not yet recruiting, 
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    Phase classification, Enrollment change, Trial completion date:  Cerebrolycin for Treatment of Covid-related Anosmia and Ageusia (clinicaltrials.gov) -  Jan 3, 2023   
    P3,  N=250, Completed, 
    These observations suggest that cerebrolysin actively protects spinal cord pathology and hyperalgesia following nerve lesion and its exacerbation with metal NPs, not reported earlier. Phase classification: P4 --> P3 | N=100 --> 250 | Trial completion date: Mar 2021 --> Oct 2022
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    Journal:  A progressive view on the treatment and rehabilitation of acute ischemic stroke (Pubmed Central) -  Dec 31, 2022   
    The authors recommend using an individual approach to the treatment of patients with acute IS and identify patients in whom neurotrophic therapy will bring the greatest effect. In addition, it is concluded that pharmacological support is an integral part of the rehabilitation of patients after a stroke, along with the correct assessment of neurological deficits, the timely start of rehabilitation measures, the complexity and continuity at all stages.
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    ABETA AND TAU LEVELS IN PLASMA NEURON-DERIVED EXTRACELLULAR VESICLES (NDEV) IN ALZHEIMER'S DISEASE: DIAGNOSTIC AND THERAPEUTIC VALUE (EXHIBITION) -  Dec 23, 2022 - Abstract #ADPD2023ADPD_1334;    
    In addition, it is concluded that pharmacological support is an integral part of the rehabilitation of patients after a stroke, along with the correct assessment of neurological deficits, the timely start of rehabilitation measures, the complexity and continuity at all stages. The present results demonstrate the utility of NDEV determinations of pathologic and synaptic proteins as effective AD biomarkers, as markers of AD severity, and as potential tools for monitoring the effects of anti -AD drugs
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    Journal:  Cerebrolysin induces hair repigmentation associated to MART-1/Melan-A reactivation. (Pubmed Central) -  Nov 23, 2022   
    Impregnation and immunostaining analysis were performed on scalp biopsies taken before and after Cerebrolysin treatment; the results showed greater melanin and melanocyte marker MART-1/Melan-A staining following Cerebrolysin treatment. We present, to our knowledge, the first report on hair repigmentation is a previously not described effect occurring following Cerebrolysin treatment.
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    Clinical, Journal:  Modulation of Amyloid-β and Tau in Alzheimer's Disease Plasma Neuronal-Derived Extracellular Vesicles by Cerebrolysin® and Donepezil. (Pubmed Central) -  Nov 16, 2022   
    We present, to our knowledge, the first report on hair repigmentation is a previously not described effect occurring following Cerebrolysin treatment. The present results demonstrate the utility of NDEV determinations of pathologic and synaptic proteins as effective AD biomarkers, as markers of AD severity, and as potential tools for monitoring the effects of anti-AD drugs.
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    Journal:  Cerebrolysin Use in Patients with Liver Damage-A Translational Study. (Pubmed Central) -  Nov 16, 2022   
    The use of Cerebrolysin did not improve short-term memory nor rescued cell multiplication in the hippocampus after MCD food intake. Understanding the neuroprotective and neurotrophic effects that drugs have on NAFLD patients can significantly contribute to a suitable therapeutic approach.
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    FEASIBILITY STUDY OF CEREBROLYSIN THERAPY IN PRE-HOSPITAL TREATMENT OF PATIENTS WITH ACUTE STROKE (GALLERY) -  Nov 7, 2022 - Abstract #WSC2022WSC_1557;    
    Understanding the neuroprotective and neurotrophic effects that drugs have on NAFLD patients can significantly contribute to a suitable therapeutic approach. Pre-hospital initiation of Cerebrolysin in acute stroke patients is feasible and allows hyperacute delivery of cytoprotective therapy.
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    CEREBROLYSIN AS ADD-ON THERAPY IN SPINAL CORD STROKE – OUR EXPERIENCE (GALLERY) -  Nov 7, 2022 - Abstract #WSC2022WSC_1442;    
    Pre-hospital initiation of Cerebrolysin in acute stroke patients is feasible and allows hyperacute delivery of cytoprotective therapy. Cerebrolysin according to our results is a safe add-on drug in patients with spinal cord stroke with promising results which warrant further investigations in this type of stroke.
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    Review:  Nutritional interventions to support acute mTBI recovery. (Pubmed Central) -  Nov 1, 2022   
    These interventions included omega-3 fatty acids (DHA and EPA), vitamin D, mineral magnesium oxide, amino acid derivative N-acetyl cysteine, hyperosmolar sodium lactate, and nootropic cerebrolysin demonstrated positive recovery outcomes, such as symptom resolution, improved cognitive function, and replenished nutrient deficiencies (vitamin D) for patients post mTBI...However, due to the heterogenicity nature of the studies available at present, it is not possible to make definitive recommendations. The systematic review conducted following the PRISMA guidelines protocol was registered (CRD42021226819), on Prospero.